FDA Draft Guidance on Acyclovir Enables DiTEBA’s Novel IV Approach to Achieve Biowaiver Status, Replacing Clinical Trials

March 30, 2017

DiTEBA is pleased to announce it has developed a novel in vitro approach to qualify acyclovir cream products for biowaiver status in accordance with the recently released FDA draft guidance on acyclovir.

Read More

DiTEBA publishes new IVRT/IVPT E-Book to assist industry with new drug submissions

May 25, 2016


Do you know what is required to ensure FDA/regulatory compliance for your submission? Download our comprehensive IVRT/IVPT E-Book to gain an in-depth knowledge of this increasingly required, but often challenging, testing method for semisolid drugs.

Read More

CROs are increasing their IVRT capacity as FDA emphasizes its use for topical/transdermal drug submissions

October 21, 2015


For a number of reasons, from issues with oral dosage first-pass metabolism of the liver, the acidic environment of the gastrointestinal tract, and problems of absorption in the stomach, to an aging population who have a hard time swallowing pills orally (pediatric patients also fall into this category), the clinical need for alternatives to oral solid dosage delivery has never been greater.

Read More

DiTEBA Registered as Drug Establishment with U.S. FDA

July 21, 2014

DiTEBA logo

NDI ADRL Inc. dba DiTEBA, Nutrasource's analytical and testing facility, is pleased to announce that its registration with the U.S. FDA has been seamlessly transitioned to the new corporate name.

It is now registered with the FDA in accordance with Section 510 (i) of the Food, Drug and Cosmetic Act and 21 CRF 207.40 as Drug Establishment (Registration No. 3005415167). DiTEBA has been registered with FDA since 2005.